Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rF-TRICOM in Metastatic Melanoma
NCT00087373Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant fowlpox-TRICOM in melanoma, sponsored by National Cancer Institute. Primary endpoints: Local response defined as complete response (CR), a partial response (PR) stable disease (SD), or progressive disease (PD) in the injected lesion according to RECIST criteria up to 15 years and Overall clinical response (CR or PR) as measured by RECIST criteria up to 15 years. Started Jun 2004; status: terminated.
02
Drugs
recombinant fowlpox-TRICOM
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00087373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087373.